Company / Depreciation & Amortization
UroGen Pharma Ltd. Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$307.0K
FY2025
5-year range
$307.0K / $924.0K
FY2021-FY2025
Trend
-61.7%
vs FY2024
Sector context
#145 of 168
Health Care
What the data says
UroGen Pharma Ltd.'s depreciation & amortization of $307,000 is lower than 86% of companies in the Health Care sector (FY2025). Depreciation & Amortization has fluctuated over the past 10 years, ranging from $200,000 in FY2019 to $924,000 in FY2023.
Based on SEC 10-K filings.
$307,000 in FY2025 with a 5-year CAGR of +0.5%.
Improved from $924,000 to $307,000 over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -28.2%
- 5-Year CAGR
- +0.5%
- 10-Year CAGR
- -
Sector benchmark
-99.9% below sector average
Key checks
Key Insights
- 5-year CAGR of +0.5%, indicating consistent growth.
- In FY2025, depreciation & amortization decreased 61.7% year-over-year.
- Ranks #145 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -5.09 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $307.0K | -61.7% |
| FY2024 | $802.0K | -13.2% |
| FY2023 | $924.0K | +11.2% |
| FY2022 | $831.0K | +0.0% |
| FY2021 | $831.0K | +177.0% |
| FY2020 | $300.0K | +50.0% |
| FY2019 | $200.0K | -50.0% |
| FY2018 | $400.0K | +100.0% |
| FY2017 | $200.0K | +0.0% |
| FY2016 | $200.0K | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026